Suppr超能文献

炎症性肠病缺铁性贫血的管理:一项系统评价

Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.

作者信息

Nielsen Ole Haagen, Ainsworth Mark, Coskun Mehmet, Weiss Günter

机构信息

From the Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark (OHN, MA, MC); and Department of Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria (GW).

出版信息

Medicine (Baltimore). 2015 Jun;94(23):e963. doi: 10.1097/MD.0000000000000963.

Abstract

Anemia is the most frequent complication of inflammatory bowel disease (IBD), but anemia, mostly due to iron deficiency, has long been neglected in these patients. The aim was to briefly present the pathophysiology, followed by a balanced overview of the different forms of iron replacement available, and subsequently, to perform a systematic review of studies performed in the last decade on the treatment of iron-deficiency anemia in IBD. Given that intravenous therapies have been introduced in the last decade, a systematic review performed in PubMed, EMBASE, the Cochrane Library, and the websites of WHO, FDA, and EMA covered prospective trials investigating the management of iron-deficiency anemia in IBD published since 2004. A total of 632 articles were reviewed, and 13 articles (2906 patients) with unique content were included. In general, oral supplementation in iron-deficiency anemia should be administered with a target to restore/replenish the iron stores and the hemoglobin level in a suitable way. However, in patients with IBD flares and inadequate responses to or side effects with oral preparations, intravenous iron supplementation is the therapy of choice. Neither oral nor intravenous therapy seems to exacerbate the clinical course of IBD, and intravenous iron therapy can be administered even in active disease stages and concomitantly with biologics. In conclusion, because many physicians are in doubt as to how to manage anemia and iron deficiency in IBD, there is a clear need for the implementation of evidence-based recommendations on this matter. Based on the data presented, oral iron therapy should be preferred for patients with quiescent disease stages and trivial iron deficiency anemia unless such patients are intolerant or have an inadequate response, whereas intravenous iron supplementation may be of advantage in patients with aggravated anemia or flares of IBD because inflammation hampers intestinal absorption of iron.

摘要

贫血是炎症性肠病(IBD)最常见的并发症,但在这些患者中,主要由缺铁引起的贫血长期以来一直被忽视。目的是简要介绍其病理生理学,随后全面概述可用的不同形式的铁替代疗法,然后对过去十年中关于IBD缺铁性贫血治疗的研究进行系统评价。鉴于静脉内疗法在过去十年中已被引入,在PubMed、EMBASE、Cochrane图书馆以及世界卫生组织、美国食品药品监督管理局和欧洲药品管理局的网站上进行的系统评价涵盖了自2004年以来发表的关于IBD缺铁性贫血管理的前瞻性试验。共审查了632篇文章,纳入了13篇(2906例患者)具有独特内容的文章。一般来说,缺铁性贫血的口服补充剂应以适当方式恢复/补充铁储备和血红蛋白水平为目标进行给药。然而,对于IBD发作且对口服制剂反应不足或出现副作用的患者,静脉补充铁剂是首选治疗方法。口服和静脉治疗似乎都不会加重IBD的临床病程,静脉铁剂治疗甚至可以在疾病活动期并与生物制剂同时使用。总之,由于许多医生对如何管理IBD中的贫血和缺铁存在疑问,显然需要就此事实施基于证据的建议。根据所提供的数据,对于疾病处于静止期且缺铁性贫血较轻的患者,应首选口服铁剂治疗,除非此类患者不耐受或反应不佳,而静脉补充铁剂可能对贫血加重或IBD发作的患者有益,因为炎症会妨碍肠道对铁的吸收。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1995/4616486/52ab11901c39/medi-94-e963-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验